Marathon Asset Management 13F: Cuts Teleflex (TFX) Stake by $4.4M

On October 26, 2026, Marathon Asset Management reduced its stake in Teleflex Incorporated (TFX) by 35,585 shares, bringing its total to 109,764 shares. This move was disclosed in the fund's latest Form 13F filing with the SEC.

Marathon's cut in Teleflex shares represents a 24.5% decrease in its position. The total value of its remaining shares is approximately $13.7 million, which accounts for about 1.09% of its overall portfolio.

TFX Teleflex Incorporated

$136.80 ▲ +12.66% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Where Teleflex Fits in Marathon's Portfolio

Teleflex ranks 32nd among Marathon's 76 reported positions. The recent cut reflects a strategic adjustment, as the fund has reduced its holdings in this stock.

Teleflex Incorporated Stock Up 0.2%

As of October 27, 2026, Teleflex shares were recently trading around $136.80. This price is about 4.5% above the 50-day moving average of $130.88 and 10% above the 200-day average of $124.37. However, it remains about 5.7% below its 52-week high of $145.00.

Recent Earnings

Teleflex reported trailing twelve-month revenue of approximately $2.25 billion, with a revenue growth of 28.9% year-over-year. The company has not been profitable recently, as it reported a net margin of -45.8% with an EPS of -$8.48. The next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Teleflex Incorporated

Recently, several insiders made purchases of Teleflex shares. On August 5, 2025, Director Stuart A Randle bought 1,000 shares at an average price of $115.86, totaling $115,860. Director Andrew A Krakauer and CEO Liam J Kelly also purchased shares on the same date, with their totals being $115,250 and $172,605, respectively. These purchases indicate insider confidence despite the recent stock adjustments.

Analysts Set New Price Targets

On September 28, 2026, B of A Securities upgraded Teleflex to a Buy rating with a price target of $158. This was a change from their previous target of $145. Truist Securities maintained a Hold rating with a target of $142 on October 14, 2026. Currently, the consensus recommendation is a Buy with a mean price target of $154 from 11 analysts.

About Teleflex

Teleflex Incorporated designs and manufactures medical devices used in critical care and surgical applications around the world. The company focuses on single-use devices that facilitate various diagnostic and therapeutic procedures, making its products essential in the healthcare sector.

Bottom Line

Marathon Asset Management's recent cut in Teleflex shares highlights ongoing adjustments in its investment strategy. Investors should keep an eye on the upcoming earnings report on November 5, 2026, for further insights into the company’s performance.